Decreased fractalkine and increased IP-10 expression in aged brain of APP(swe) transgenic mice
- PMID: 18095157
- DOI: 10.1007/s11064-007-9554-z
Decreased fractalkine and increased IP-10 expression in aged brain of APP(swe) transgenic mice
Abstract
Chemokines and their receptors have been strongly implicated in the inflammatory process and pathogenesis of the neurodegenerative disorders, such as Alzheimer's disease (AD). In the present study, we examined the expression of chemokines, fractalkine, interferon-inducible protein-10 (IP-10) and macrophage inflammatory protein-1alpha (MIP-1alpha) by immunohistochemistry in the brain of transgenic mice APP SWE (Tg2576) at ages of 9, 11, and 17 months, which over-express a mutated form of human amyloid precursor protein (APP). Decreased fractalkine and increased IP-10 expression in cerebral cortex and hippocampus were found at ages of 9 and 17 months in Tg2576 mice when compared with age-matched control mice. On the contrary, MIP-1alpha expression showed no difference between Tg2576 mice and aged controls and was not influenced by ages. beta-amyloid (Abeta) positive plaques were co-located with the intense IP-10 expression. The finding suggests fractalkine and IP-10 may participate in the pathogenesis of AD; and could be new therapeutic strategies for neuroprotection.
Similar articles
-
Effects of CX3CR1 and Fractalkine Chemokines in Amyloid Beta Clearance and p-Tau Accumulation in Alzheimer's Disease (AD) Rodent Models: Is Fractalkine a Systemic Biomarker for AD?Curr Alzheimer Res. 2016;13(4):403-12. doi: 10.2174/1567205013666151116125714. Curr Alzheimer Res. 2016. PMID: 26567742 Review.
-
β-Amyloid, cholinergic transmission, and cerebrovascular system -- a developmental study in a mouse model of Alzheimer's disease.Curr Pharm Des. 2013;19(38):6749-65. doi: 10.2174/13816128113199990711. Curr Pharm Des. 2013. PMID: 23530514
-
Impacts of aging and amyloid-β deposition on plasminogen activators and plasminogen activator inhibitor-1 in the Tg2576 mouse model of Alzheimer's disease.Brain Res. 2015 Feb 9;1597:159-67. doi: 10.1016/j.brainres.2014.11.042. Epub 2014 Nov 29. Brain Res. 2015. PMID: 25454795
-
Vascular endothelial growth factor (VEGF) affects processing of amyloid precursor protein and beta-amyloidogenesis in brain slice cultures derived from transgenic Tg2576 mouse brain.Int J Dev Neurosci. 2009 Oct;27(6):517-23. doi: 10.1016/j.ijdevneu.2009.06.011. Epub 2009 Jul 7. Int J Dev Neurosci. 2009. PMID: 19589380
-
Pyroglutamate-modified amyloid-β protein demonstrates similar properties in an Alzheimer's disease familial mutant knock-in mouse and Alzheimer's disease brain.Neurodegener Dis. 2014;14(2):53-66. doi: 10.1159/000353634. Epub 2013 Oct 23. Neurodegener Dis. 2014. PMID: 24158021
Cited by
-
Insight into the emerging and common experimental in-vivo models of Alzheimer's disease.Lab Anim Res. 2023 Dec 11;39(1):33. doi: 10.1186/s42826-023-00184-1. Lab Anim Res. 2023. PMID: 38082453 Free PMC article. Review.
-
Infiltrating CD8+ T cells exacerbate Alzheimer's disease pathology in a 3D human neuroimmune axis model.Nat Neurosci. 2023 Sep;26(9):1489-1504. doi: 10.1038/s41593-023-01415-3. Epub 2023 Aug 24. Nat Neurosci. 2023. PMID: 37620442
-
EVOO Polyphenols Exert Anti-Inflammatory Effects on the Microglia Cell through TREM2 Signaling Pathway.Pharmaceuticals (Basel). 2023 Jun 27;16(7):933. doi: 10.3390/ph16070933. Pharmaceuticals (Basel). 2023. PMID: 37513845 Free PMC article.
-
Chemokines in patients with Alzheimer's disease: A meta-analysis.Front Aging Neurosci. 2023 Mar 9;15:1047810. doi: 10.3389/fnagi.2023.1047810. eCollection 2023. Front Aging Neurosci. 2023. PMID: 36967827 Free PMC article.
-
Fractalkine/CX3CR1-Dependent Modulation of Synaptic and Network Plasticity in Health and Disease.Neural Plast. 2023 Jan 4;2023:4637073. doi: 10.1155/2023/4637073. eCollection 2023. Neural Plast. 2023. PMID: 36644710 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
